TY -的T1 -一个随机试验的强的松< em >和< / em >强的松和伊曲康唑过敏性支气管肺的曲霉病急性期合并哮喘JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01787 -2021欧元SP - 2101787 AU Agarwal:非盟- Muthu Valliappan盟——SehgalInderpaul Singh AU - Dhooria, Sahajal AU - Prasad, Kuruswamy Thurai AU - Garg, Mandeep AU - Aggarwal, ashtosh Nath AU - Chakrabarti，Arunaloke Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/09/02/13993003.01787 - 2021. -抽象N2 -糖皮质激素和抗真菌三唑是否优于单独糖皮质激素,在减少急性加重,患者的过敏性支气管肺的曲霉病(ABPA)仍然是未知的。我们的目的是比较强的松龙-伊曲康唑联合与强的松龙单药治疗ABPA的疗效和安全性。我们随机选取treatment-naïve急性期ABPA合并哮喘患者，分别接受强的松龙单独治疗(4个月)或强的松龙与伊曲康唑联合治疗(分别4个月和6个月)。主要结果是12个月时的加重率和开始治疗24个月内糖皮质激素依赖性ABPA。关键的次要结果是6周时的应答率和血清总IgE下降百分比，首次ABPA恶化的时间，以及治疗紧急不良反应(AE)。我们随机抽取191名受试者接受强的松龙(n=94)或强的松龙-伊曲康唑联合治疗(n=97)。强的松龙组和强的松龙-伊曲康唑组的1年加重率分别为33%和20.6% (p=0.054)。没有参与者进展到糖皮质激素依赖性ABPA。所有受试者在6周时均出现复合反应，血清总IgE下降(平均下降47.6% vs . 45.5%)。 The mean time to first ABPA exacerbation (417 days) was not different between the groups. None of the participants required modification of therapy due to AE.There was a trend towards a decline in ABPA exacerbations at 1-year with the prednisolone-itraconazole combination than prednisolone monotherapy. A three-arm trial comparing itraconazole and prednisolone monotherapies with their combination, preferably in a multicentric design, is required to define the best treatment strategy for acute-stage ABPA.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: RA has received grant support for conducting research in ABPA from Cipla Pharmaceuticals, Mumbai, India, outside the submitted work.Conflict of interest: VM has nothing to disclose.Conflict of interest: ISS has nothing to disclose.Conflict of interest: SD has nothing to disclose.Conflict of interest: KTP has nothing to disclose.Conflict of interest: MG has nothing to disclose.Conflict of interest: ANA has nothing to disclose.Conflict of interest: AC has nothing to disclose. ER -